Vorbipiprant
Based on 1 Customer Validation
Vorbipiprant (CR6086) is an orally active EP4 receptor antagonist with high selectivity for the human EP4 receptor (Ki: 16.6 nM). Vorbipiprant has immunomodulatory, anti-inflammatory, antitumor, and anti-angiogenic activities. Vorbipiprant can inhibit the expression of multiple pro-inflammatory cytokines and the activation of immune cells, and convert "cold" tumors unresponsive to immune checkpoint inhibitors into "hot" tumors. Vorbipiprant is used in the research of diseases such as rheumatoid arthritis and colon cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.89%
- CAS No.: 1417742-86-9
- Formule: C26H27F3N2O3
- Masse moléculaire:472.50
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
|
human EP4-R 16.6 nM (Ki) |
IL-6 70 nM (IC50) |
IL-23 608 nM (IC50) |
IL-17 |
MMP-9 |
Vorbipiprant (0.01-30 μM; 3-24 h) dose-dependently reduces LPS (HY-D1056) and PGE2-induced IL-6 and VEGF gene expression in human THP-1-derived macrophages, with IC50 values of 70 and 25 nM, respectively[1].
Vorbipiprant (0.01-30 μM; 24 h) dose-dependently decreases PGE2-stimulated IL-23 release in human dendritic cells, with an IC50 of 608 nM[1].
Vorbipiprant (0.03-10 μM; 48 h) dose-dependently inhibits PGE2-induced IL-17 release in human Th17 cells, with complete inhibition at 1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vorbipiprant (30 mg/kg; oral administration; 14 days) exhibits antitumor activity in a mouse colon cancer model when used in combination with an anti-PD-1 monoclonal antibody[2].
Pharmacokinetic Analysis in Rats[1]
| Dose (mg/kg) and Route | 1 and p.o. | 3 and p.o. | 10 and p.o. | 15 and p.o. | 30 and p.o. |
| Cmax (ng/mL) | 1250 | 3230 | 14500 | 11900 | 34500 |
| tmax (h) | 0.25 | 0.25 | 0.5 | 0.5 | 1 |
| AUC (ng·h/mL) | 2170 | 13700 | 58000 | 61600 | 206000 |